National trials involving lymphatic mapping for melanoma: The multicenter selective lymphadenectomy trial, the SunBelt melanoma trial, and the Florida melanoma trial

Seminars in Oncology

Volumn 31, Issue 3, 2004, Pages 363-373

  Reintgen, Douglas ^a   Pendas, Solange ^a   Jakub, James ^a   Swor, Gray ^a   Giuliano, Rosemary ^a   Bauer, Jan ^a   Cassall, Robert ^a   Duhaime, Lisa ^a   Alsarrai, Marwin ^a   Shivers, Steve ^a  

^a Lakeland Regional Cancer Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; BIOLOGICAL MARKER; GANGLIOSIDE; GLYCOPROTEIN GP 100; MELAN A; MELANOMA ANTIGEN 1; MELANOMA VACCINE;

BONE MARROW SUPPRESSION; CANCER ADJUVANT THERAPY; CANCER STAGING; CANCER SURVIVAL; CLINICAL TRIAL; DRUG MEGADOSE; FOLLOW UP; HUMAN; LIVER TOXICITY; LOW DRUG DOSE; LYMPH NODE DISSECTION; LYMPHADENECTOMY; MELANOMA; MENTAL DISEASE; PRIORITY JOURNAL; RADIOSURGERY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; REVIEW; SENTINEL LYMPH NODE BIOPSY; SIDE EFFECT; STAINING; STATISTICAL SIGNIFICANCE; WORLD HEALTH ORGANIZATION;

EID: 3042800121     PISSN: 00937754     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.seminoncol.2004.03.017     Document Type: Article

References (21)

1. Kirkwood J.M, Strawderman M.H., Ernstoff M.S., et al. Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma The Eastern Cooperative Oncology Group Trial EST 1684. J Clin Oncol. 14:1996;7-17
2. Kirkwood J., Ibrahim J.G., Sondak V., et al. High- and low-dose interferon alfa 2-b in high-risk melanoma First analysis of Intergroup trial E1690/S9111/C9190. J Clin Oncol. 18:2000;2444-2458
3. Kirkwood J.M., Ibrahim J., Sosman J.A., et al. High- and low-dose interferon alfa-2b significantly prolongs relapse-free and overall survival compared with GM2-KLH/QS-21 vaccine in patients with resected stage IIB-III melanoma Results of intergroup trial E1694/S9512/C509801. J Clin Oncol. 19:2001;2370-2380
4. Shivers S.C., Wang X., Li W., et al. Molecular staging of malignant melanoma Correlation with clinical outcome. JAMA. 280:1998;1410-1415
5. Goydos J.S., Ravikumar T.S., Germino F.J., et al. Minimally invasive staging of patients with melanoma Sentinel lymphadenectomy and detection of the melanoma-specific proteins MART-1 and tyrosinase by reverse transcriptase polymerase chain reaction. J Am Coll Surg. 187:1998;182-188
6. Bostick P.J., Morton D.L., Turner R.R., et al. Prognostic significance of occult metastases detected by sentinel lymphadenectomy and reverse transcriptase-polymerase chain reaction in early-stage melanoma patients. J Clin Oncol. 17:1999;3238-3244
7. Roshdich B., Haddad F., Messina J., et al. The role of complete lymph node dissection in malignant melanoma patients with a positive sentinel lymph node biopsy A retrospective review of the Moffitt Cancer Center experience. Eur J Nuclear Med. 26:(suppl):1999;S58. abstr
8. Chu K.U., Turner R.R., Hansen N.M., et al. Sentinel node metastasis in patients with breast carcinoma accurately predicts immunohistochemically detectable nonsentinel node metastasis. Ann Surg Oncol. 6:1999;756-761
9. Wrightson W.R., Edwards E., Albrecht J., et al. Reverse transcriptase-polymerase chain reaction (RT-PCR) analysis of histologically negative nonsentinel nodes in melanoma. J Surg Res. 93:2000;341. (abstr)
10. Thompson J.F., McCarthy W.H., Robinson E., et al. Sentinel lymph node biopsy in 102 patients with clinical stage 1 melanoma undergoing elective lymph node dissection. 47th Cancer Symposium. 1994;Society of Surgical Oncology, Houston, TX. March(abstr)
11. Gershenwald J.E., Tseng C.H., Thompson W., et al. Improved sentinel lymph node localization in patients with primary melanoma with the use of radiolabeled colloid. Surgery. 124:1998;203-210
12. Byrd D., Nason K., Eary J., et al. Utility of sentinel lymph node dissection in patients with head and neck melanoma. 54th Annual Cancer Symposium. 2001;15-18 Society of Surgical Oncology, Washington, DC. March (abstr)
13. McMasters K.M., Edwards M., Ross M., et al. Frequency of non-sentinel lymph node metastases in melanoma. 54th Annual Cancer Symposium. 2001;15-18 Society of Surgical Oncology, Washington, DC. March (abstr)
14. Balch C.M., Soong S., Ross M., et al. Long-term results of a multi-institutional randomized trial comparing prognostic factors and surgical results for intermediate thickness melanoma (1.0 to 4.0 mm). Ann Surg Oncol. 7:2000;87-97
15. Gershenwald J., Thompson W., Mansfield P., et al. Patterns of failure in melanoma patients after successful lymphatic mapping and a negative SLN biopsy. 1996;21-24 Society of Surgical Oncology, Atlanta, GA. (abstr) March
16. Balch C.M. Surgical management of melanoma Results of prospective randomized trials. Ann Surg Oncol. 5:1998;301-309
17. Veronesi U., Adamus J., Bandiera D.C., et al. Inefficacy of immediate node dissection in stage I melanoma of the limbs. N Engl J Med. 297:1977;627-630
18. Cascinelli N., Morabito A., Santinami M., et al. Immediate or delayed dissection of regional nodes in patients with melanoma of the trunk A randomized trial. Lancet. 351:1998;793-796
19. Norman J., Cruse C.W., Wells K., et al. A redefinition of skin lymphatic drainage by lymphoscintigraphy for malignant melanoma. Am J Surg. 162:1991;432-437
20. Balch C.M., Soong S.U., Bartolucci A.A., et al. Efficacy of elective regional lymph node dissection of 1-4 mm thick melanomas for patients 60 years of age and younger. Ann Surg. 224:1996;255-266
21. Balch C.M., Soong S., Ross M., et al. Long-term results of a multi-institutional randomized trial comparing prog-nostic factors and surgical results for intermediate thick-ness melanoma (1.0 to 4.0 mm). Ann Surg Oncol. 7:2000;87-97